Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 13/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103170 | 0.89 | TBXA2R (0.48) | TBXA2RDRD2ALOX5APPTGES2KDM4E | |
| SCHEMBL3088456 | 0.88 | TBXA2R (0.48) | TBXA2RDRD2ALOX5APPTGES2KDM4E | |
| SCHEMBL3100317 | 0.88 | TBXA2R (0.59) | TBXA2RALOX5APPTGES2KDM4EMAPT | |
| SCHEMBL3094297 | 0.85 | ALOX5AP (0.49) | TBXA2RALOX5AP | |
| SCHEMBL12966490 | 0.84 | TBXA2R (0.47) | TBXA2RDRD2TP53ALDH1A1NOD2 | |
| SCHEMBL25968148 | 0.81 | ALOX5AP (0.47) | TBXA2RALOX5APPTGES2TP53KDM4E | |
| SCHEMBL23270808 | 0.80 | ALOX5AP (0.44) | TBXA2RALOX5APPTGES2KDM4EMAPT | |
| SCHEMBL30181540 | 0.80 | ALOX5AP (0.44) | TBXA2RALOX5APPTGES2KDM4EMAPT | |
| SCHEMBL3098657 | 0.78 | PTGES2 (0.50) | TBXA2RALOX5APPTGES2KDM4EMAPT | |
| SCHEMBL23270786 | 0.78 | PTGES2 (0.53) | ALOX5APPTGES2TP53KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1933842-B1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | PANMIRA PHARMACEUTICALS LLC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-7795274-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795274-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795274-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-7405302-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405302-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405302-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| WO-2007047207-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | TBXA2R 97/4885DRD2 4349/4885ALOX5AP 4/4885 |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | TBXA2R 97/4885DRD2 4349/4885ALOX5AP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.